DEMONSTRATION AND QUANTITATION OF ACTIVATION OF
THE FIRST COMPONENT
OF COMPLEMENT IN HUMAN SERUM*

BY ROBERT J. ZICCARDI AND NEIL R. COOPER
(From the Department of Molecular Immunology, Scripps Clinic and Research Foundation, La Jolla, California 92037)

The first component of human complement (C1) is comprised of three glycoprotein subunits, Clq,Clr, and Cls, held together in a calcium-dependent complex (1-3). The interaction of the Clq subunit with immune complexes triggers a series of intramolecular changes in the C1 molecule leading to the conversion of Clr and Cls from inactive precursor molecules to active proteases, thus initiating the classical complement pathway, and with it the numerous biological manifestations of complement (4-8). Although physicochemical changes in the individual subunits have been documented (9-12), the correlates of these events in macromolecular C1 have not been thoroughly analyzed.

We have recently reported that macromolecular C1 as well as free Cls can be directly demonstrated and quantitated in human serum by single and double immunodiffusion techniques. In the course of these studies it became apparent that activated C1 gave a very different precipitation pattern than native C1 with antisera to Clq, Clr, and Cls in double immunodiffusion analyses. The progressive changes in the C1 Ouchterlony pattern, which are due to C1 dissociation and also alterations in antigenicity of the subunits, are described here. Furthermore, it is possible to measure some of these alterations by single radial diffusion techniques and thus directly quantitate C1 activation in human sera.

Materials and Methods

Materials and Proteins. Methods for the purification and characterization of Clq, Clr, and Cls from human serum and for the production of monospecific antisera to each have been published (12-14). Fresh human serum was obtained from healthy donors. Bovine serum albumin was purchased from Calbiochem (San Diego, Calif.). IgG was isolated from the pseudoglobulin fraction of human serum (5 mM ethylene-diaminetetra-acetic acid (EDTA), pH 5.4) by ion exchange chromatography on diethylaminoethyl cellulose in phosphate-buffered saline at pH 7.3.

* Publication no. 1381 from Scripps Clinic and Research Foundation. Supported by U. S. Public Health Service grant CA 14692, a program project grant AI 07907, and Grant-in-Aid 77-941 from the American Heart Association.

Abbreviations used in this paper: agg IgG, heat aggregated IgG; C1, first component of human complement; CH50, dilution of serum giving 50% lysis of sensitized erythrocytes in the test system; EDTA, ethylene-diaminetetra-acetic acid; NHS, normal human serum.

R. J. Ziccardi, and N. R. Cooper. 1978. Direct demonstration and quantitation of the first complement component in human serum. Science (Wash. D. C.). In press.

THE JOURNAL OF EXPERIMENTAL MEDICINE • VOLUME 147, 1978 385
FIG. 1. Effect of temperature on the immunodiffusion pattern of C1 in human serum.
Normal human serum was allowed to diffuse in agarose containing calcium for 48 h at 4°C (left panel) or 22°C (right panel). The single fused precipitin line observed at 4°C represents intact C1 as Clq, Clr, and Cls antigens are on the same molecule. A very different pattern was obtained at 22°C.

The IgG obtained was essentially pure judged by polyacrylamide gel electrophoresis in sodium dodecyl sulfate. Aggregation of IgG was achieved by incubation of a 10 mg/ml sample at 63°C for 20 min after which particulate aggregates were removed by centrifugation in a Beckman Microfuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.).

Agarose was purchased from Marine Colloids, Inc., Springfield, N. J., sodium barbital from Sigma Chemical Co., St. Louis, Mo., particulate inulin from Pfannstiehl Labs., Inc., Waukegan, Ill., and zymosan from Nutritional Biochemicals Corp., Cleveland, Ohio. Lipopolysaccharides from the heptose-deficient rough mutant Salmonella Minnesota R-595 was kindly provided by Dr. D. Morrisen, Scripps Clinic and Research Foundation, La Jolla, Calif.

Hemolytic Assays. Titrations of the complement activity of serum (CHs) and the hemolytic activity of C4 in human serum were carried out by published procedures (15, 16).

Immunochemical Analyses. Immunodiffusion analyses were performed in agarose in barbital-buffered saline, pH 7.2, 0.6 × physiological ionic strength containing 2.5 mM calcium as described earlier. All immunodiffusion studies were carried out for 48 h at 4°C or room temperature as specified. 1 and 0.8% agarose was used for single radial and double immunodiffusion, respectively. The concentrations of anti-C1q, anti-Clr, and anti-Clr or mixtures thereof used in the single radial diffusion analyses were determined as described earlier.

Immunoelectrophoresis was performed in agarose in barbital-buffered saline pH 8.6, 0.6 × physiological ionic strength, containing 2.5 mM calcium. Electrophoresis was carried out for 4 h at 20 mA per slide at 4°C.

Results

Activation of C1 in Serum during Immunodiffusion Studies at 22°C. As we have reported earlier, antisera to Clq, Clr, and Cls gave a reaction of identity when reacted at 4°C with normal human sera in double diffusion analyses in agarose containing calcium. Grossly different Ouchterlony patterns were obtained, however, when identical studies were carried out at room temperature (Fig. 1). Under these conditions multiple crossing lines were
TABLE I

| Amount Agg IgG added to NHS | Percent complement consumption | | |
|-----------------------------|-------------------------------|---|---|
| mg/ml | C4 | CH50 |
| None | 0 | 0 |
| 0.2 | 32 | 43 |
| 0.5 | 100 | 100 |
| 1.0 | 100 | 100 |
| 2.0 | 100 | 100 |

obtained with anti-C1q, anti-C1r, and anti-C1s. It seemed likely that the observed changes in the double diffusion patterns reflected activation of C1 secondary to interaction with agarose during the diffusion process at 22°C. Consistent with this interpretation, serum incubated for 5 h at room temperature with 50 mg/ml of agarose lost 55% of its CH50, 36% of its C4, and 40% of its C2 activity, while serum not treated with agarose lost only 6, 4, and 9%, respectively, on incubation at room temperature. All values were compared to serum samples kept at 0°C for the same periods of time.

Double Immunodiffusion Analyses of Activated C1 in Human Serum. In these experiments, fresh human serum was treated for 60 min at 37°C with aggregated IgG to activate serum C1. A 10-fold range of activator input was examined. As shown in Table I, complement activation, as indicated by CH50 depletion, and C1 activation, as evidenced by C4 consumption, were evident after incubation of serum with 0.2 mg/ml of aggregated IgG. These samples were subjected to double immunodiffusion analyses at 4°C as depicted in Fig. 2. Whereas the control serum gave the typical fused precipitin line characteristic of C1 with anti-C1q, anti-C1r and anti-C1s, a markedly different pattern was observed on analyzing the sera containing activated C1 (Fig. 2). Changes in the precipitin lines representing C1 as well as those due to C1q, C1r, and C1s reacting with their respective antibodies were observed. The continuous C1 precipitin line produced by anti-C1q, anti-C1r, and anti-C1s reacting with C1 in serum disappeared as the dose of aggregated IgG increased. In the case of C1q, spurring of the line produced by anti-C1q over that generated by anti-C1r was evident by the second dose of aggregated IgG, 0.5 mg/ml, and the intensity of the spur increased further with the dose of aggregates. Simultaneously, the intensity of the precipitin reaction of C1r with its antiserum progressively decreased with increasing amounts of aggregated Ig and no clear C1r precipitin line was apparent by 2 mg/ml of aggregated IgG. Spurring of the anti-C1s precipitin line over the lines produced by anti-C1q and anti-C1r was evident with the lowest dose of aggregated IgG. The intensity of this spur increased with the addition of progressively larger amounts of aggregated IgG to the serum. Results very similar to these were obtained with another C1 activator, bacterial lipopolysaccharide R-595. Spurring of the C1s line was observed when serum was treated with 0.2 mg/ml R-595 and disappearance of the C1r line was evident with 2 mg/ml R-595. On the other hand, nonaggregated IgG (2 mg/ml), inulin (20 mg/ml), and zymosan (5 mg/ml) produced minimal if any changes in the C1 immunodiffusion pattern.
Demonstration and Quantitation of C1 Activation

**FiG. 2. Effect of activation on the immunodiffusion pattern of C1 in human serum.** NHS was incubated for 1 h at 37°C alone or with various concentrations of heat aggregated IgG. The mixtures were subjected to double immunodiffusion analyses at 4°C in agarose containing calcium. Activation of C1 in serum was accompanied by a progressive change in the immunodiffusion pattern.

**Dissociation of C1 in Human Serum with Activation.** The most likely interpretation of the changing Ouchterlony pattern detailed above was that C1 was undergoing progressive dissociation with increasing doses of C1 activator. While single radial diffusion studies of untreated normal human serum (NHS) in agarose containing equivalent concentrations of antibodies to C1q, C1r, and C1s together yielded a single precipitin ring, multiple rings (two to three) were observed in identical studies of serum treated with complement activators, strongly supporting the concept that C1 was undergoing dissociation.

Release of C1s from C1 in serum with activation was directly demonstrated by immuno-electrophoretic analyses of serum containing activated C1 in agarose in the presence of calcium (Fig. 3). Untreated normal serum or serum incubated with nonaggregated IgG showed a precipitin line with anti-C1s around the well of application, as is characteristic of native C1 in serum. After incubation with aggregated IgG, however, free C1s was detected in the serum (Fig. 3).

**Quantitation of C1s Released with C1 Activation.** C1s released during activation of C1 in serum was quantitated by single radial immunodiffusion analyses in agarose containing calcium. To differentiate free C1s from C1s in macromolecular C1, high concentrations of antibody to C1q were incorporated.
ROBERT J. ZICCARDI AND NEIL R. COOPER

389

Fig. 3. Demonstration of release of Cls with activation of C1 in human serum. Human serum was incubated for 1 h at 37°C with 2 mg/ml of nonaggregated IgG (NHS) or aggregated IgG (NHS), and then subjected to immunoelectrophoretic separation in agarose containing calcium. Simultaneously, Cls and Cls, each at a concentration of 30 μg/ml, were analyzed. The pattern was developed with anti-Cls. Release of Cls with activation is evident.

Progressive Loss of Clr Antigenicity with C1 Activation. The double immunodiffusion studies described above demonstrate a diminution in intensity of the Clr precipitin line with the addition of increasing doses of aggregated IgG to serum (Fig. 2). Consistent with this finding, quantitative radial diffusion studies in the presence of EDTA showed a progressive reduction in serum Clr antigen content as greater amounts of activator were added to the serum (Table II). It should be noted that no change in Clr content was observed on addition to serum of the same concentrations of nonaggregated IgG. Thus the Clr content decreased from 79% of the untreated serum value with an activator dose of 0.2 mg/ml to 19% with a dose of 2.0 mg/ml. On the other hand, no change in total Cls content in the sera treated with the same doses of activator was observed (Table II). With the exception of the highest activator dose, C1q content also did not change. Therefore, C1 activation in serum can be detected into the agarose to confine the Cls in the C1 complex to a precipitin ring at the application well, while low concentrations of antibody to Cls were employed to quantitate free Cls. 13, 24, 32, and 39 μg/ml of free Cls were detected in serum incubated with 0.2, 0.5, 1.0, and 2.0 mg/ml aggregated IgG, respectively (Fig. 4). The highest activator concentration released all of the Cls from the C1 in this serum. No free Cls was detected in untreated serum or serum treated with the same doses of nonaggregated IgG.
FIG. 4. Quantitation of Cls released with activation of C1 in human serum. NHS was incubated for 1 h at 37°C alone or with various concentrations of heat aggregated IgG. The mixtures were subjected to single radial immunodiffusion analyses at 4°C in agarose containing calcium and a high concentration of antibody to Clq to confine the intact C1 to a precipitin ring immediately surrounding the well of application. Low concentrations of anti-Cls were also incorporated into the agarose to permit quantitation of released Cls. The progressive release of Cls with increasing activator dose is evident (center column). The immunodiffusion plates also contained various amounts of isolated Cls (not shown) to serve as standards for quantitation of released Cls (right column). No free Cls was detected in untreated serum or serum treated with the same doses of nonaggregated IgG.

as a decrease in the Clr:Cls ratio from the value of 1.0 characteristic of normal serum (Table II).

Discussion

Macromolecular C1 can be detected in normal human serum as a continuous line of precipitation induced by anti-C1q, anti-C1r, and anti-C1s in double immunodiffusion studies performed at 4°C, as we have previously noted. Very
TABLE II
Quantitation of Clq,Clr, and Cls in Human Serum Treated with Various Doses of Aggregated IgG

| Amount agg IgG added to NHS* mg/ml | Percent of untreated serum concentration† | Ratio             |
|-----------------------------------|------------------------------------------|-------------------|
|                                   | Clq | Clr | Cls | Clq/Cls | Clr/Cls |
| None                             | 100 | 85  | 85  | 1.18     | 1.00    |
| 0.2                              | 100 | 79  | 82  | 1.22     | 0.96    |
| 0.5                              | 90  | 38  | 80  | 1.13     | 0.48    |
| 1.0                              | 89  | 25  | 79  | 1.13     | 0.32    |
| 2.0                              | 64  | 19  | 80  | 0.80     | 0.24    |

* All samples were incubated at 37°C for 1 h.
† Determined by single radial immunodiffusion in agarose containing EDTA (17).

different Ouchterlony patterns were observed when the diffusion studies were performed at room temperature (Fig.1). The double diffusion patterns at room temperature were found to be characteristic of activated C1 in serum and identical patterns were obtained at 4°C with serum previously incubated with complement activators such as aggregated IgG or R-595 lipopolysaccharide. In this regard agarose was noted to effectively activate C1 in serum at 22°C.

It is apparent that the patterns obtained with serum containing C1 are similar to those obtained with serum containing C1 dissociated by addition of EDTA although there are differences. Dissociation of Clq and Cls from C1 with activation is shown by the spurs of the precipitin lines produced by these components reacting with their respective antisera over that of C1 (Figs. 1 and 2). Release of Cls, as shown by the spur, is evident at the lowest activator dose examined (0.2 mg/ml) while dissociation of Clq is only apparent with higher activator doses, suggesting that Cls is released at an earlier stage in the activation process than Clq. Interestingly, the Clq precipitin line does not penetrate or cross the precipitin line due to released Cls, presumably because the released Clq bound to the Cls-anti-Cls immune complex. Release of Cls from the C1 complex with activation was also demonstrated by immunoelectrophoretic studies (Fig. 3). Additionally, single radial immunodiffusion analyses of serum containing activated C1 yielded multiple rings in agarose containing antisera to Clq, Clr, and Cls. Although dissociation of C1 with activation has not previously been directly demonstrated, Laurell et al. found Clr and Cls with various electrophoretic mobilities in the sera of patients with certain diseases (18), which is consistent with dissociation. Bartholomew and Esser postulated dissociation with activation as they were unable to find C1 in sucrose density gradient analyses of activated serum.3

Perhaps the most surprising change in the Ouchterlony pattern of serum containing activated C1 is the progressive decrease in intensity of the Clr precipitin line with the addition of increasing amounts of aggregated IgG (or R-595) to serum (Fig. 2). In fact, no clear cut Clr precipitin line was evident on

3 R. M. Bartholomew, and A. F. Esser. 1977. Exchange of radiolabeled Cls into serum C1 and its application in a simplified activation assay. J. Immunol. In press.
addition of aggregated IgG to a concentration of 2 mg/ml. There are four possible explanations for the loss in Clr antigenicity with activation. First, Clr after activation may become bound to the activating substance and thus be unable to diffuse into the agarose. This hypothesis requires that activated Clr bind firmly to each of the activators examined, i.e., aggregated IgG, LPS-R-595 and agarose, as loss of Clr antigenicity was observed with each. A second possibility is that activated Clr, like Clq and activated Cls, is released during C1 activation but then spontaneously aggregates, thus escaping detection with anti-C1r. Isolated Clr converted into Clr by incubation at 37°C does in fact aggregate (R. J. Ziccardi and N. R. Cooper, unpublished observations). Third, the antigenicity of Clr may be lost because of structural rearrangements following the peptide bond cleavage which occurs with Clr activation (9). However, Clr and Clr formed by incubation of Clr at 37°C (9) give a reaction of identity using the same anti-C1r in double immunodiffusion analyses in agarose containing EDTA with no trace of spurring and there is also no evidence of a reduction in intensity of the precipitin line of Clr reacting with the antiserum (unpublished observation). Nevertheless, it is possible that further changes occur in the Clr molecule with activation of C1 in serum leading to the production of a form of Clr different from that which was generated in vitro. A fourth possibility is that Clr antigenicity becomes completely masked by Clq, Cls, or both in C1. This is not likely, as Clr antigenicity in C1 is also not apparent on performing the studies in EDTA (Table II) which dissociates C1. A related possibility is that Clr binds to C1 inactivator which completely masks its antigenicity. This interaction is known to be calcium independent. In this regard, Laurell et al. (18) felt Clr was present in a Clr-C1 inactivator complex in certain pathological sera although they were unable to show precipitation with antisera to Clr. Experiments are underway to differentiate between these hypotheses.

Although the explanation for the loss in Clr antigenicity with activation is not yet clear, this observation, along with the finding that Cls antigenicity does not change with activation, furnishes a practical approach to quantitating C1 activation in serum. The Clr:Cls molar ratio in normal human serum is known to be unity (3). A decrease in the Clr:Cls molar ratio, as determined by quantitative single radial diffusion studies, reflects the extent of activation (Table II).

An alternative approach to quantitating C1 activation in serum is based on the finding that Cls is released during the activation process (Fig. 3). Released Cls can be quantitated in the presence of macromolecular C1 by performing radial diffusion analyses in agarose containing high concentrations of anti-C1q, to confine C1 to the area around the application well, and lesser concentrations of anti-Cls to permit free Cls to produce a measurable ring of precipitation. The quantity of Cls released from C1 was found to be proportional to the dose of activator added to the serum (Fig. 4).

In another paper, techniques were presented which permit the quantitation of C1 and free C1 subunits in normal human sera, while the present study describes two alternative approaches to the detection and quantitation of activation of C1 in normal human serum. Presently, intact C1 can be only measured by hemolytic techniques which involve specialized reagents and multiple steps (19) and activated C1 can be measured by more complex
hemolytic techniques (20) or by indirect approaches based on its ability to
inactivate C2 and C4 (21). There is no practical published method to quantitate
free C1 subunits in the presence of macromolecular C1. The techniques
presented here and in the other paper will thus be useful in analyzing the
properties and levels of macromolecular C1 and certain aspects of the activation
process.

The present approaches to quantitating C1, free C1 subunits and C1 activa-
tion in human sera have a potentially wider range of usefulness as they may
be of value in following the status of the complement system in the serum of
patients with certain diseases. Reduced levels of C1 are found in serum of
patients with several diseases (22) and there is also evidence for the presence of
free C1 subunits in some pathologic sera (18). de Bracco and Manni found
several patients with decreased C1r:C1s ratios although a large pool of normals
and pathological sera considered together in their studies yielded a constant
C1r:C1s ratio (23). Circulating activated C1 is probably present in the serum of
patients with complement consumptive process such as systemic lupus erythe-
matosus as such sera frequently show strikingly reduced levels of C2 and C4
(22). The approaches presented here should permit a differentiation of disease
related changes in synthesis of C1 subcomponents from consumptive processes.
A reduction in the concentrations of C1q, C1r, and C1s with maintenance of an
equimolar ratio would suggest a coordinate reduction in synthesis of the
subcomponents while a selective reduction of the C1r level with no change in
the C1q:C1s molar ratio would indicate activation.

It remains to be determined whether the techniques presented here will be of
sufficient sensitivity to be of value in achieving the above aims with patients' sera. While these approaches appear to be relatively insensitive in detecting
activation of C1 in serum induced by aggregated IgG, results obtained with
this activator obviously cannot be extrapolated directly to pathologic sera
containing immune complexes or other complement activators. Hopefully the
techniques will prove to be of aid in monitoring the status of the complement
system in patients.

Summary

Activation of the first component of human complement (C1) in human sera
can be readily detected in double immunodiffusion studies with anti-C1q, anti-
C1r, and anti-C1s as it produces a characteristic pattern quite different from
that of precursor C1. Native macromolecular C1 gives a continuous line of
precipitation with antisera to C1q, C1r, and C1s in double diffusion studies.
After activation of C1 by incubation of serum with complement activators,
three major changes occurred in the Ouchterlony pattern. First, spurring of
the C1s precipitin line over that of macromolecular C1, indicating release of
C1s from C1, was observed with low doses of activator. Release of C1s was
quantitated by single radial diffusion and shown to be complete with the
highest activator dose examined. Second, C1q was released with larger activator
doses as shown also by spurring of the precipitin line due to this component
over the remaining macromolecular C1. Third, and most surprising, C1r
antigenicity was progressively lost as the activator dose was increased and no
C1r line remained with the highest dose of activator tested. This was not true
with C1s as there was no change in the total C1s concentration in serum incubated with various activator doses.

These observations provide two approaches to the quantitation of C1 activation in human serum. First, C1r and C1s can be quantitated by single radial diffusion. A decrease in the C1r:C1s ratio correlates with activation. Second, C1s released by the activation can be quantitated by single radial diffusion if the agarose contains high concentrations of anti-C1q to confine C1, also containing C1s, to the area near the application well, and lesser concentrations of anti-C1s to permit free C1s to produce a measurable ring. The extent of release of C1s also correlates with activation.

These immunochemical techniques to quantitate C1 activation directly in serum do not require specialized reagents. It is hoped that they will be useful in screening pathological sera and in monitoring the status of the complement system in patients.

We wish to thank Julie Harper Ziccardi for technical assistance and Carol Davis for secretarial services.

Received for publication 19 August 1977.

References

1. Lepow, I. H., G. B. Naff, E. W. Todd, J. Pensky, and C. F. Hinz. 1963. Chromatographic resolution of the first component of human complement into three activities. J. Exp. Med. 117:983.
2. Naff, G. B., J. Pensky, and I. H. Lepow. 1964. The macromolecular nature of the first component of human complement. J. Exp. Med. 119:593.
3. Ziccardi, R. J., and N. R. Cooper. 1977. The subunit composition and sedimentation properties of Human Cl. J. Immunol. 118:2047.
4. Müller-Eberhard, H. J. 1969. Complement. Ann. Rev. Biochem. 38:389.
5. Lepow, I. H., O. D. Ratnoff, F. S. Rosen, and L. Pillemer. 1956. Observations on a pro-esterase associated with partially purified first component of human complement (C'1). Proc. Soc. Exp. Biol. Med. 92:32.
6. Becker, E. L. 1956. Concerning the mechanism of complement action. II. The nature of the first component of guinea pig complement. J. Immunol. 77:469.
7. Naff, G. B., and O. D. Ratnoff. 1968. The enzymatic nature of C'1r. Conversion of C'1s to C'1 esterase and digestion of amino acid esters by C'1r. J. Exp. Med. 128:571.
8. Barkas, T., G. K. Scott, and J. E. Fothergill. 1973. Purification, characterization and active-site studies in human serum subcomponent C1s. Biochem. Soc. Trans. 1:1219.
9. Ziccardi, R. J., and N. R. Cooper. 1976. Activation of C1r by proteolytic cleavage. J. Immunol. 116:504.
10. Gigli, I., R. R. Porter, and R. B. Sim. 1976. The unactivated form of the first component of human complement Cl. Biochem. J. 157:541.
11. Sakai, K., and R. M. Stroud. 1973. Purification, molecular properties and activation of C1 proesterase, C1s. J. Immunol. 110:1010.
12. Valet, G., and N. R. Cooper. 1974. Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J. Immunol. 112:339.
13. Calcott, M. A., and H. J. Müller-Eberhard. 1972. C1q protein of human complement. Biochemistry. 11:3443.
14. Ziccardi, R. J., and N. R. Cooper. 1976. Physicochemical and functional characterization of the Clr subunit of the first complement component. J. Immunol. 116:496.
15. Mayer, M. M. 1961. Complement and complement fixation. In: Experimental Immuonochemistry. E. A. Kabat and M. M. Mayer, editors. Charles C. Thomas, Springfield, Ill. p. 133.
16. Schreiber, R. D., and H. J. Müller-Eberhard. 1974. Fourth component of human complement: description of a three polypeptide chain structure. J. Exp. Med. 140:1324.
17. Mancini, G., A. O. Carbonara, and J. F. Heremans. 1965. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 2:235.
18. Laurell, A.-B., U. Mårtensson, and A. G. Sjoholm. 1976. C1 subcomponent complexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol. Microbiol. Scand. Sect. C. 84:455.
19. Borsos, T., and H. R. Rapp. 1963. Chromatographic separation of the first component of complement and its assay on a molecular basis. J. Immunol. 91:851.
20. Colten, H. R., T. Borsos, and H. J. Rapp. 1969. Titration of the first component of complement on a molecular basis: Suitability of IgM and unsuitability of IgG hemolysins as sensitizer. Immunochemistry. 6:461.
21. Donaldson, U. H., and F. S. Rosen. 1964. Action of complement in hereditary angioneurotic edema: The role of C1 esterase. J. Clin. Invest. 43:2204.
22. Schur, P. H., and K. F. Austen. 1968. Complement in human disease. Annu. Rev. Med. 19:1.
23. de Bracco, M. M. E., and J. A. Manni. 1974. Serum levels of Clq, Clr and Cls in normal and pathological sera. Arthritis Rheum. 17:121.